BIOMAT Database Logo BIOMAT Database Logo

Insulin vs sulfonylureas for second-line diabetes treatment. 2014

Ilker Tasci, and Umut Safer
Department of Internal Medicine, Gulhane School of Medicine, Ankara, Turkey.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Ilker Tasci, and Umut Safer
Insulin vs sulfonylureas for second-line diabetes treatment.
January 2014, JAMA,
Ilker Tasci, and Umut Safer
Insulin vs sulfonylureas for second-line diabetes treatment--reply.
January 2014, JAMA,
Ilker Tasci, and Umut Safer
Insulin vs sulfonylureas for second-line diabetes treatment--reply.
January 2014, JAMA,
Ilker Tasci, and Umut Safer
Sulfonylureas as second line treatment for type 2 diabetes.
July 2018, BMJ (Clinical research ed.),
Ilker Tasci, and Umut Safer
Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
January 2018, Annals of internal medicine,
Ilker Tasci, and Umut Safer
First-line vs second-line antibiotics for treatment of sinusitis.
March 2002, JAMA,
Ilker Tasci, and Umut Safer
Insulin for type 2 diabetes: choosing a second-line insulin regimen.
November 2008, International journal of clinical practice,
Ilker Tasci, and Umut Safer
Insulin and oral sulfonylureas in the treatment of diabetes mellitus.
August 1992, American pharmacy,
Ilker Tasci, and Umut Safer
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective.
January 2021, ClinicoEconomics and outcomes research : CEOR,
Ilker Tasci, and Umut Safer
Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.
August 2023, Primary care diabetes,
Copied contents to your clipboard!